Effects of estrogen on growth and smooth muscle differentiation of vascular wall-resident CD34(+) stem/progenitor cells

Atherosclerosis. 2015 Jun;240(2):453-61. doi: 10.1016/j.atherosclerosis.2015.04.008. Epub 2015 Apr 9.

Abstract

Objectives: To investigate the effects of estrogen on growth and smooth muscle cell (SMC)-differentiation of vascular wall-resident CD34(+) stem/progenitor cells (VRS/Pcs).

Methods and results: The existence of CD34(+) VRS/Pcs was confirmed by immunohistochemistry in the adventitia of arteries of young (2-month-old) and old (24-month-old) female SD rats with less CD34(+) adventitial cells detected in the old. The VRS/Pcs isolated from young animals were grown in Stem cell growth medium or induced to differentiate into SMC with PDGF-BB in the presence or absence of 17β-estrodiol (E2). Flow cytometry, RT-qPCR and Western blot showed that E2 promoted Brdu incorporation of the CD34(+) VRS/Pcs growing in Stem cell growth medium; but when the cells were incubated in PDGF-BB, the hormone enhanced their expression of SMC marker SM22. ChIP and IP assays showed that E2 significantly promoted the binding of pELK1-SRF complex to the promoter of c-fos gene in CD34(+) VRS/Pcs growing in the Stem cell growth medium; but when the cells were stimulated with PDGF-BB, an E2-enhanced binding of myocardin-SRF to the promoter of SM22 gene was found with enhanced expression of SRC3 and its binding to myocardin. The effects of E2 above could be blocked by the estrogen receptor antagonist ICI 182,780 or inhibited by SRF-siRNA.

Conclusion: Estrogen has dual effects on CD34(+) VRS/Pcs. For the undifferentiated VRS/Pcs, it accelerates their proliferation by enhancing binding of pELK1-SRF complex to c-fos gene; while for the differentiating VRS/Pcs, it promotes their differentiation to SMC through a mechanism of SRC3-mediated interaction of myocardin-SRF complex with SM22 gene.

Keywords: Differentiation; Estrogen; Proliferation; Vascular wall-resident stem/progenitor cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, CD34 / metabolism*
  • Becaplermin
  • Binding Sites
  • Biomarkers / metabolism
  • Cell Differentiation / drug effects*
  • Cell Differentiation / genetics
  • Cell Proliferation / drug effects*
  • Cell Proliferation / genetics
  • Cell Separation
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Estradiol / pharmacology*
  • Estrogen Antagonists / pharmacology
  • Female
  • Gene Expression Regulation
  • Genes, fos
  • Microfilament Proteins / metabolism
  • Multipotent Stem Cells / metabolism
  • Multipotent Stem Cells / pathology*
  • Muscle Development / drug effects*
  • Muscle Proteins / metabolism
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / metabolism
  • Myocytes, Smooth Muscle / drug effects*
  • Myocytes, Smooth Muscle / metabolism
  • Nuclear Proteins / metabolism
  • Nuclear Receptor Coactivator 3 / metabolism
  • Promoter Regions, Genetic
  • Proto-Oncogene Proteins c-sis / pharmacology
  • RNA Interference
  • Rats, Sprague-Dawley
  • Serum Response Factor / genetics
  • Serum Response Factor / metabolism
  • Time Factors
  • Trans-Activators / metabolism
  • Transfection
  • ets-Domain Protein Elk-1 / metabolism

Substances

  • Antigens, CD34
  • Biomarkers
  • Elk1 protein, rat
  • Estrogen Antagonists
  • Microfilament Proteins
  • Muscle Proteins
  • Nuclear Proteins
  • Proto-Oncogene Proteins c-sis
  • Serum Response Factor
  • Trans-Activators
  • ets-Domain Protein Elk-1
  • myocardin
  • transgelin
  • Becaplermin
  • Estradiol
  • Nuclear Receptor Coactivator 3